China Approves Sinopharm's Covid Vaccine for General Use

The transcript discusses the approval and distribution of Sinopharm's COVID-19 vaccine in China. It highlights the challenges of public acceptance due to past pharmaceutical scandals and transparency issues compared to Western vaccines. The vaccine's distribution advantages, such as not requiring ultra-cold storage, make it appealing to emerging markets. Efforts to vaccinate millions before the Lunar New Year are underway, leveraging existing testing infrastructure.

What is the name of the unit under Sinopharm responsible for the vaccine discussed?

• Beijing Institute of Biological Products

• Sinovac Biotech

• Wuhan Institute of Biological Products

• China National Biotec Group

What is a major concern regarding the acceptance of the vaccine in China?

• High cost of the vaccine

• Lack of production capacity

• Past pharmaceutical scandals

• Limited distribution channels

How does the Sinopharm vaccine differ from those developed by Pfizer and Moderna?

• It is easier to distribute due to less stringent storage requirements

• It uses mRNA technology

• It requires very low storage temperatures

• It is more expensive

What discrepancy in vaccine efficacy data was highlighted between the UAE and China?

• The UAE reported 80% efficacy, while China reported 70%

• The UAE reported 75% efficacy, while China reported 80%

• The UAE reported 90% efficacy, while China reported 85%

• The UAE reported 86% efficacy, while China reported 79.3%

What is China's target for vaccination before the Lunar New Year?

• 100 million people

• 20 million people

• 10 million people

• 50 million people

Which group of workers has already been prioritized for vaccination in China?

• Teachers

• Retired citizens

• Frontline workers and state-owned company employees

• Students

What infrastructure is China leveraging to aid in the vaccine rollout?

• Mobile vaccination units

• Existing testing infrastructure

• Newly built hospitals

• International aid